Drugs / Investigational RSV+hMPV vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06686654 | Nov 2024 → Jan 2027 expected | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Investigational RSV+hMPV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06686654 ↗ |
| Modality | Vaccine | “bivalent hMPV/RSV mRNA vaccine candidate” NCT06686654 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06686654 ↗ |